Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.

Buziashvili M, Mirtskhulava V, Kipiani M, Blumberg HM, Baliashvili D, Magee MJ, Furin JJ, Tukvadze N, Kempker RR.

Int J Tuberc Lung Dis. 2019 Sep 1;23(9):1005-1011. doi: 10.5588/ijtld.18.0626.

PMID:
31615608
2.

A human rights-based approach to tuberculosis diagnosis.

Furin J, Frick M, McKenna L.

Int J Tuberc Lung Dis. 2019 Aug 1;23(8):959. doi: 10.5588/ijtld.19.0023. No abstract available.

PMID:
31533888
3.

Challenges and controversies in childhood tuberculosis.

Reuter A, Hughes J, Furin J.

Lancet. 2019 Sep 14;394(10202):967-978. doi: 10.1016/S0140-6736(19)32045-8. Review.

PMID:
31526740
4.

The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM; Lancet Respiratory Medicine drug-resistant tuberculosis Commission group.

Lancet Respir Med. 2019 Sep;7(9):820-826. doi: 10.1016/S2213-2600(19)30263-2. Review.

PMID:
31486393
5.

Protecting those who serve: are we doing enough to prevent tuberculosis in healthcare workers?

Furin J, Sotgiu G.

Eur Respir J. 2019 Apr 18;53(4). pii: 1900485. doi: 10.1183/13993003.00485-2019. Print 2019 Apr. No abstract available.

PMID:
31000668
6.

The STREAM trial: missed opportunities and lessons for future clinical trials.

Loveday M, Reuter A, Furin J, Seddon JA, Cox H.

Lancet Infect Dis. 2019 Apr;19(4):351-353. doi: 10.1016/S1473-3099(19)30106-9. Epub 2019 Mar 22. No abstract available.

7.

Building a tuberculosis-free world: The Lancet Commission on tuberculosis.

Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione MC, Sharman A, Small PM, Swaminathan S, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Agins BD, Alexandru S, Andrews JR, Beyeler N, Bivol S, Brigden G, Cattamanchi A, Cazabon D, Crudu V, Daftary A, Dewan P, Doepel LK, Eisinger RW, Fan V, Fewer S, Furin J, Goldhaber-Fiebert JD, Gomez GB, Graham SM, Gupta D, Kamene M, Khaparde S, Mailu EW, Masini EO, McHugh L, Mitchell E, Moon S, Osberg M, Pande T, Prince L, Rade K, Rao R, Remme M, Seddon JA, Selwyn C, Shete P, Sachdeva KS, Stallworthy G, Vesga JF, Vilc V, Goosby EP.

Lancet. 2019 Mar 30;393(10178):1331-1384. doi: 10.1016/S0140-6736(19)30024-8. Epub 2019 Mar 20. Review. No abstract available.

PMID:
30904263
8.

Tuberculosis.

Furin J, Cox H, Pai M.

Lancet. 2019 Apr 20;393(10181):1642-1656. doi: 10.1016/S0140-6736(19)30308-3. Epub 2019 Mar 20. Review.

PMID:
30904262
9.

A gastric resident drug delivery system for prolonged gram-level dosing of tuberculosis treatment.

Verma M, Vishwanath K, Eweje F, Roxhed N, Grant T, Castaneda M, Steiger C, Mazdiyasni H, Bensel T, Minahan D, Soares V, Salama JAF, Lopes A, Hess K, Cleveland C, Fulop DJ, Hayward A, Collins J, Tamang SM, Hua T, Ikeanyi C, Zeidman G, Mule E, Boominathan S, Popova E, Miller JB, Bellinger AM, Collins D, Leibowitz D, Batra S, Ahuja S, Bajiya M, Batra S, Sarin R, Agarwal U, Khaparde SD, Gupta NK, Gupta D, Bhatnagar AK, Chopra KK, Sharma N, Khanna A, Chowdhury J, Stoner R, Slocum AH, Cima MJ, Furin J, Langer R, Traverso G.

Sci Transl Med. 2019 Mar 13;11(483). pii: eaau6267. doi: 10.1126/scitranslmed.aau6267.

PMID:
30867322
10.

Making the case: developing innovative adherence solutions for the treatment of tuberculosis.

Verma M, Furin J, Langer R, Traverso G.

BMJ Glob Health. 2019 Feb 1;4(1):e001323. doi: 10.1136/bmjgh-2018-001323. eCollection 2019. No abstract available.

11.

Healthcare Provider Discrimination toward Pregnant Women with Rifampin-Resistant Tuberculosis.

Loveday M, Hlangu S, Furin J.

Emerg Infect Dis. 2019 Mar;25(3):609-610. doi: 10.3201/eid2503.181571.

12.

Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis.

Osman M, Harausz EP, Garcia-Prats AJ, Schaaf HS, Moore BK, Hicks RM, Achar J, Amanullah F, Barry P, Becerra M, Chiotan DI, Drobac PC, Flood J, Furin J, Gegia M, Isaakidis P, Mariandyshev A, Ozere I, Shah NS, Skrahina A, Yablokova E, Seddon JA, Hesseling AC; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR TB.

Emerg Infect Dis. 2019 Mar;25(3):441-450. doi: 10.3201/eid2503.180852.

13.

Universal regimens or universal access to drug susceptibility testing for tuberculosis?

Acquah R, Furin J.

Lancet Infect Dis. 2019 Mar;19(3):224-225. doi: 10.1016/S1473-3099(18)30742-4. Epub 2019 Feb 8. No abstract available.

PMID:
30744961
14.

Advances in the diagnosis, treatment, and prevention of tuberculosis in children.

Furin J.

Expert Rev Respir Med. 2019 Mar;13(3):301-311. doi: 10.1080/17476348.2019.1569518. Epub 2019 Jan 22.

PMID:
30648437
15.

Revising the definition of extensively drug-resistant tuberculosis.

Lange C, Chesov D, Furin J, Udwadia Z, Dheda K.

Lancet Respir Med. 2018 Dec;6(12):893-895. doi: 10.1016/S2213-2600(18)30428-4. Epub 2018 Nov 9. No abstract available.

PMID:
30420247
16.

Demanding an end to tuberculosis: treatment of tuberculosis infection among persons living with and without HIV.

Fargher J, Reuter A, Furin J.

Curr Opin HIV AIDS. 2019 Jan;14(1):21-27. doi: 10.1097/COH.0000000000000517.

PMID:
30407203
17.

QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment.

Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, Cox V, Tommasi M, Furin J, Chiang CY, Quelapio M, Koura KG, Trébucq A, Padanilam X, Dravniece G, Piubello A.

Int J Tuberc Lung Dis. 2018 Oct 26. doi: 10.5588/ijtld.18.0423. [Epub ahead of print]

PMID:
30366516
18.

Treatment of Multidrug-Resistant Tuberculosis Infection in Children.

Cruz AT, Garcia-Prats AJ, Furin J, Seddon JA.

Pediatr Infect Dis J. 2018 Oct;37(10):1061-1064. doi: 10.1097/INF.0000000000002135. No abstract available.

PMID:
30216296
19.

Reducing harm in the treatment of multidrug-resistant tuberculosis.

Reuter A, Furin J.

Lancet. 2018 Sep 8;392(10150):797-798. doi: 10.1016/S0140-6736(18)31670-2. No abstract available.

PMID:
30215367
20.

Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis.

Seddon JA, Schaaf HS, Marais BJ, McKenna L, Garcia-Prats AJ, Hesseling AC, Hughes J, Howell P, Detjen A, Amanullah F, Singh U, Master I, Perez-Velez CM, Misra N, Becerra MC, Furin JJ.

Lancet Respir Med. 2018 Sep;6(9):662-664. doi: 10.1016/S2213-2600(18)30329-1. No abstract available.

21.

Drug-resistant tuberculosis: will grand promises fail children and adolescents?

Furin J, Tommasi M, Garcia-Prats AJ.

Lancet Child Adolesc Health. 2018 Apr;2(4):237-238. doi: 10.1016/S2352-4642(18)30068-3. Epub 2018 Mar 13. No abstract available.

PMID:
30169295
22.

Providing quality care on the border with Haiti.

Koenig SP, Furin J.

Lancet. 2018 Aug 4;392(10145):382. doi: 10.1016/S0140-6736(18)31489-2. No abstract available.

PMID:
30102166
23.

Bedaquiline use in South Africa reveals a lifesaving policy in action.

Reuter A, Furin J.

Lancet Respir Med. 2018 Sep;6(9):653-655. doi: 10.1016/S2213-2600(18)30280-7. Epub 2018 Jul 11. No abstract available.

PMID:
30001995
24.

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.

Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, Menzies D, Turkova A, Achar J, Amanullah F, Barry P, Becerra M, Chan ED, Chan PC, Ioana Chiotan D, Crossa A, Drobac PC, Fairlie L, Falzon D, Flood J, Gegia M, Hicks RM, Isaakidis P, Kadri SM, Kampmann B, Madhi SA, Marais E, Mariandyshev A, Méndez-Echevarría A, Moore BK, Nargiza P, Ozere I, Padayatchi N, Ur-Rehman S, Rybak N, Santiago-Garcia B, Shah NS, Sharma S, Shim TS, Skrahina A, Soriano-Arandes A, van den Boom M, van der Werf MJ, van der Werf TS, Williams B, Yablokova E, Yim JJ, Furin J, Hesseling AC; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB.

PLoS Med. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. eCollection 2018 Jul.

25.

Treatment of Multidrug-resistant Tuberculosis Infection in Children.

Cruz AT, Garcia-Prats AJ, Furin J, Seddon JA.

Pediatr Infect Dis J. 2018 Aug;37(8):831-834. doi: 10.1097/INF.0000000000002087. Review. No abstract available.

26.

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.

Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, Daniels J, De Azevedo V, Kock Y, Steele SJ, Shroufi A, Ade S, Alikhanova N, Benedetti G, Edwards J, Cox H, Furin J, Isaakidis P.

Eur Respir J. 2018 Jun 14;51(6). pii: 1800017. doi: 10.1183/13993003.00017-2018. Print 2018 Jun.

27.

Pan-tuberculosis regimens: an argument against.

Dheda K, Gumbo T, Lange C, Horsburgh CR Jr, Furin J.

Lancet Respir Med. 2018 Apr;6(4):240-242. doi: 10.1016/S2213-2600(18)30097-3. No abstract available.

PMID:
29595502
28.

Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.

Cox V, Brigden G, Crespo RH, Lessem E, Lynch S, Rich ML, Waning B, Furin J.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):407-412. doi: 10.5588/ijtld.17.0706.

PMID:
29562988
29.

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.

Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P.

Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13.

PMID:
29452942
30.

World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?

Cox V, Furin J.

Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1211-1213. doi: 10.5588/ijtld.17.0199. Erratum in: Int J Tuberc Lung Dis. 2018 Mar 1;22(3):353-354.

PMID:
29297439
31.

Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".

Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02229-17. doi: 10.1128/AAC.02229-17. Print 2018 Jan. No abstract available.

32.

Operational aspects of bedaquiline implementation in Swaziland: report from the field.

Vambe D, Dlamini T, Furin J, Gracia-Edwards C, Keus K, Kunene K, Shabangu A, Dlamini SN, Sikhondze W.

Public Health Action. 2017 Sep 21;7(3):240-242. doi: 10.5588/pha.17.0054.

33.

Cross-sectional interview study of fertility, pregnancy, and urogenital schistosomiasis in coastal Kenya: Documented treatment in childhood is associated with reduced odds of subfertility among adult women.

Miller-Fellows SC, Howard L, Kramer R, Hildebrand V, Furin J, Mutuku FM, Mukoko D, Ivy JA, King CH.

PLoS Negl Trop Dis. 2017 Nov 27;11(11):e0006101. doi: 10.1371/journal.pntd.0006101. eCollection 2017 Nov.

34.

Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis.

Furin J, Lessem E, Cox V.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701552. doi: 10.1183/13993003.01552-2017. Print 2017 Nov. No abstract available.

35.

The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?

Reuter A, Tisile P, von Delft D, Cox H, Cox V, Ditiu L, Garcia-Prats A, Koenig S, Lessem E, Nathavitharana R, Seddon JA, Stillo J, von Delft A, Furin J.

Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1114-1126. doi: 10.5588/ijtld.17.0468. Review.

PMID:
29037291
36.

Missed opportunities for earlier diagnosis of rifampicin-resistant tuberculosis despite access to Xpert® MTB/RIF.

Mohr E, Daniels J, Muller O, Furin J, Chabalala B, Steele SJ, Cox V, Dolby T, Ferlazzo G, Shroufi A, Duran LT, Cox H.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1100-1105. doi: 10.5588/ijtld.17.0372.

37.

Bedaquiline or delamanid for rifampin-resistant tuberculosis?

Lessem E, Cox V, Furin J.

Lancet Respir Med. 2017 Oct;5(10):772-774. doi: 10.1016/S2213-2600(17)30309-0. Epub 2017 Sep 5. No abstract available.

PMID:
28887015
38.

Prevention of hearing loss in patients with multidrug-resistant tuberculosis.

Cox H, Reuter A, Furin J, Seddon J.

Lancet. 2017 Sep 2;390(10098):934. doi: 10.1016/S0140-6736(17)32170-0. No abstract available.

39.

Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.

Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01066-17. doi: 10.1128/AAC.01066-17. Print 2017 Oct. Erratum in: Antimicrob Agents Chemother. 2017 Dec 21;62(1):.

40.

To Test or Not to Test? Ending the Age-Old Debate for Drug-Resistant Tuberculosis.

Furin J, Cox H.

Clin Infect Dis. 2017 Oct 1;65(7):1212-1213. doi: 10.1093/cid/cix491. No abstract available.

41.

Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?

Kunkel A, Furin J, Cohen T.

Lancet Infect Dis. 2017 Dec;17(12):e429-e433. doi: 10.1016/S1473-3099(17)30299-2. Epub 2017 May 19. Review.

PMID:
28533094
42.

Stability of Second-Line Tuberculosis Medications Mixed With Milk or Yogurt.

Harausz EP, Leigh J, Garcia-Prats AJ, Furin J, Peloquin CA.

Clin Infect Dis. 2017 Aug 15;65(4):704-705. doi: 10.1093/cid/cix434. No abstract available.

PMID:
28482036
43.

Tuberculosis innovations mean little if they cannot save lives.

Pai M, Furin J.

Elife. 2017 May 2;6. pii: e25956. doi: 10.7554/eLife.25956.

44.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
45.

The time has come: sparing injectables in paediatric MDR-TB.

Weld ED, Garcia-Prats AJ, Furin JJ, Bailey TC, Hesseling AC, Dooley KE.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30078-4. doi: 10.1016/S2213-2600(17)30078-4. [Epub ahead of print] No abstract available.

PMID:
28344008
46.

Overcoming challenges in the diagnosis, prevention, and treatment of pediatric drug-resistant tuberculosis.

Jonckheree S, Furin J.

Expert Rev Respir Med. 2017 May;11(5):385-394. doi: 10.1080/17476348.2017.1309294. Epub 2017 Mar 28. Review.

PMID:
28319425
47.

Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.

Guglielmetti L, Hewison C, Avaliani Z, Hughes J, Kiria N, Lomtadze N, Ndjeka N, Setkina S, Shabangu A, Sikhondze W, Skrahina A, Veziris N, Furin J.

Int J Tuberc Lung Dis. 2017 Feb 1;21(2):167-174. doi: 10.5588/ijtld.16.0493.

48.

Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.

Furin J, Diacon AH, Andries K.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):4-5. doi: 10.5588/ijtld.16.0768. No abstract available.

PMID:
28157457
49.

Life in the time of antiretrovirals in South Africa.

Furin J, Isaakidis P.

Lancet HIV. 2017 Mar;4(3):e95-e96. doi: 10.1016/S2352-3018(16)30222-3. Epub 2016 Dec 10. No abstract available.

PMID:
27956186
50.

New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.

Harausz EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, Hesseling AC, Achar J, Bernheimer J, Cruz AT, D'Ambrosio L, Detjen A, Graham SM, Hughes J, Jonckheere S, Marais BJ, Migliori GB, McKenna L, Skrahina A, Tadolini M, Wilson P, Furin J; Sentinel Project on Pediatric Drug-Resistant Tuberculosis.

Am J Respir Crit Care Med. 2017 May 15;195(10):1300-1310. doi: 10.1164/rccm.201606-1227CI. Review.

Supplemental Content

Support Center